In patients with ST-segment elevation myocardial infarction (STEMI) pre-infarction angina, pre-procedural TIMI flow and collateral flow to the myocardium supplied by the infarct related artery are suggested to be cardioprotective. We evaluated the effect of these factors on myocardial salvage index (MSI) and infarct size adjusting for area at risk in patients with STEMI treated with primary percutaneous coronary intervention.
Introduction
Restoration of epicardial coronary blood flow in patients with ST-segment elevation myocardial infarction (STEMI) is obtained by primary percutaneous coronary intervention (PCI) in order to minimize myocardial damage. 1 Myocardial damage can be accurately assessed using cardiac magnetic resonance (CMR) to quantify myocardial infarct size. 2 The T2-weighted CMR technique also provides a method to measure the jeopardized myocardium (the so-called area at risk). 3 -5 Thus, infarct size can be related to the area at risk and the myocardial salvage index (MSI) calculated, a parameter that appears to be associated with the prognosis in patients with STEMI. 6 In patients treated with primary PCI, several factors have been associated with cardioprotection, e.g. pre-infarction angina, pre-procedural Thrombolysis in Myocardial Infarction (TIMI) flow grade, and collateral flow to the infarct-related artery. It has been speculated that angina preceding an acute myocardial infarction (pre-infarction angina) resembles the mechanism of ischaemic preconditioning and consequently may lead to cardioprotection. 7 Ischaemic preconditioning, defined as brief episodes of ischaemia prior to the onset of infarction, is known to be cardioprotective by limiting the ischaemiareperfusion injury. 7 Data from clinical studies support this theory, 8 -14 but no clear evidence for the association between preinfarction angina myocardial salvage exists. The importance of collateral flow to the infarct-related area has been studied previously without consistent results. 15 -23 A high pre-procedural TIMI flow grade (2 and 3) of the infarct-related artery is associated with improved outcome and smaller myocardial infarct size assessed by CMR compared with pre-procedural TIMI flow 0/1. 20, 24, 25 However, it has been demonstrated that patients with pre-procedural TIMI flow 2 are at lower risk than patients with TIMI flow 0/1 and at higher risk than TIMI flow 3, 26 -28 but whether this is due to a difference in salvage has not been determined. The aim of the present study was to determine the effect of pre-infarction angina, pre-procedural TIMI flow (0/1 vs. 2 vs. 3), and collateral blood flow to the infarct-related artery on MSI and infarct size adjusted for area at risk in STEMI patients treated with primary PCI.
Methods

Study population and treatment
The patients in the present sub-study participated in a randomized study comparing intravenous administration of exenatide with placebo in STEMI patients. 29 Exenatide is a synthetic analogue to glucagon-like-peptide-1 that is used in diabetics and also suggested to be cardioprotective. The present study included patients with a first STEMI and symptom duration ≤12 h transferred via field triage or a local hospital to the PCI centre. STEMI was defined as ST-segment elevation in two contiguous ECG leads of .0.1 mV in V 4 -V 6 or limb leads II, III, and aVF, or .0.2 mV in leads V 1 -V 3 . Patients were not considered for enrolment if they presented with cardiogenic shock or were unconscious, and patients with acute stent thrombosis, known renal insufficiency, or previous coronary artery bypass graft surgery were excluded. Finally, patients with no subsequent rise in cardiac biomarkers were excluded. All patients eligible for primary PCI were pre-treated with aspirin (300 mg orally or 500 mg intravenously), clopidogrel (600 mg orally), and heparin (10 000 U intravenously) usually administered in the pre-hospital setting following field triage. On arrival at the catheterization laboratory, a coronary angiography was performed to identify the culprit lesion, and primary PCI was performed as previously described. 29 Treatment with glycoprotein IIb/IIIa receptor antagonists was administered if by the discretion of the operator and if no contraindications were present. All patients were treated with clopidogrel 75 mg daily for 12 months and aspirin 75 mg daily indefinitely. Cardiac biomarkers (troponin T) were obtained before intervention and immediately after, 6 h after, and 12-18 h after intervention. All patients were informed orally and in writing, and all gave their written consent before inclusion; the study was performed according to the Helsinki declaration of good clinical practice, and The Danish National Committee on Biomedical Research Ethics approved the protocol.
Assessment of pre-infarction angina and angiographic analysis
The patients were carefully evaluated with regard to pre-infarct angina defined as one or more episodes of angina (Canadian Cardiovascular Society class ≥1) up to 3 months before the index episode, without distinction between angina ,24 h before the infarction or .24 h. The history of angina was obtained in the recovery phase (days 1 -3) after the infarction. There was no need for the pain/discomfort to have a similar character as the symptoms related to the STEMI. A period of 3 months was chosen based on previous results. Infarct size and salvage index by cardiac magnetic resonance
In the absence of contraindications, a CMR scan was performed a median of 2 (IQR 1 -3) days after the STEMI and CMR was repeated after a median of 89 (IQR 80 -93) days as previously described. 29 Patients who did not undergo the initial scan were still considered for the second scan. Thus, the number of analysed patients varied, with 227 analysed for infarct size and 200 for area at risk. The myocardial area at risk was assessed on the first CMR scan as oedema, using a T2-weighted short tau inversion recovery sequence. 3 -5 On the second CMR examination, delayed enhancement images were obtained to determine the final infarct size, using a standard ECG-triggered inversion-recovery sequence. 2 Left ventricular volume and function were measured on both CMR examinations, using a standard ECGtriggered balanced steady-state free precession cine sequence. Area at risk (%LV), infarct size (%LV and g), MSI, and left ventricular ejection fraction (LVEF) were calculated as previously described. 29 MSI was calculated as: area at risk -infarct size/area at risk.
ST-segment resolution
After admission, patients were monitored with a 12-lead ST-monitoring ECG for continuous ST-segment changes before, during, and a minimum of 90 min after reperfusion with a monitor defibrillator (LIFEPAK 12, Medtronic Emergency Response Systems, Redmond, WA, USA). The ECG data were analysed masked to randomization, using computer software (LIFENET Case View version 6.1, Medtronic Emergency Response Systems). The lead with maximal ST-segment elevation prior to generation of re-flow was used to determine baseline ST-segment elevation. The same lead was used to evaluate whether the patients achieved 70% ST-segment resolution at 30 min after first wire.
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Statistical analysis
Continuous variables were tested for normal distribution and compared using Student's t or Mann-Whitney's tests as appropriate and accordingly expressed as mean (+SD) or median (IQR). Categorical variables were compared using the x 2 or Fisher's exact test. In case of several groups, trend analyses were performed using the Kruskal-Wallis test or one-way analysis of variances and Mann-Whitney's or Tukey's tests for post hoc analyses. Linear correlation analyses were performed using the Pearson or Spearman tests as appropriate. Multivariable regression analyses were performed using pre-infarction angina, pre-procedural TIMI flow, and collateral flow, in case P , 0.05 in the univariable analysis and adjusting these variables for any baseline variable with P ≤ 0.10 for the difference between groups and any other variables with P , 0.05 in the univariable regression analysis. To compare the relationship between the area at risk and the infarct size, a regression analysis was performed assuming normal distribution, and an analysis of covariance was used to test for equality of the regression lines for the different groups. Finally, the association between MSI and pre-infarction angina, pre-procedural TIMI flow and collateral flow were adjusted for exenatide treatment in linear regression analyses and interaction with exenatide were evaluated. A two-sided P-value , 0.05 was considered statistically significant. All statistical analyses were performed with SPSS software version 17 (SPSS, Inc., Chicago, IL, USA). Figure 1 shows the patients' disposition. A total of 40 patients (18%) had pre-infarction angina; 153 (67%) had pre-procedural TIMI flow 0/1, 38 (17%) had pre-procedural TIMI flow 2, and 36 (16%) had pre-procedural TIMI flow 3; and 26 (17% of the patients with pre-procedural TIMI flow 0/1) had collateral blood flow to the infarct-related artery. The overall number of patients included in the present study is higher than the population number in the original study, 29 because patients with multiple vessel disease were included in the present study. The baseline characteristics for patients with pre-infarction angina, pre-procedural TIMI flow, and collaterals flow are shown in Tables 1, 2 , and 3. ST-segment resolution data were missing from a total of 18 patients.
Results
Pre-infarction angina
Patients with pre-infarction angina were more frequently treated with aspirin and nitrates at the time of infarction, had a previous PCI, and more had collateral flow to the infarct-related artery compared with those without pre-infarction angina ( Table 1) . No statistically significant differences were observed between the groups with regard to any other baseline variable ( Table 1) Influence of pre-infarction angina, collateral flow, and pre-procedural TIMI flow be lower in patients with pre-infarction angina ( Table 1) , especially when adjusting for the area at risk ( Figure 3A) . No difference was observed in either ST-segment resolution, area at risk, or LVEF ( Table 1) . Pre-infarction angina was significantly associated with MSI in the univariable linear regression analysis, and the association remained significant in the multivariable model (Table 4) . Finally, the difference in MSI between patients with and without angina remained significant when stratifying the patients according to placebo (P ¼ 0.035) and exenatide treatment (P ¼ 0.027), no interaction between exenatide treatment and pre-infarction angina was observed (P ¼ 0.48), and pre-infarction angina remained significantly associated with MSI adjusting for exenatide treatment (P ¼ 0.005).
Pre-procedural TIMI flow follow-up), area at risk and peak troponin T ( Table 2) . Adjusting for the area at risk in a linear regression analysis, there was also a significant difference between TIMI flow groups (P , 0.001) ( Figure 3B) . These results identify patients with TIMI flow 2 as intermediary risk patients. Pre-procedural TIMI flow was significantly related to ST-segment resolution. Pre-procedural TIMI flow was associated with MSI in the univariable linear regression analysis, and the association remained significant in both multivariable models (Table 4) . Interestingly, an interaction between exenatide treatment and pre-procedural TIMI flow was observed (P ¼ 0.028), but pre-procedural TIMI flow remained significantly associated with MSI when stratifying the patients according to placebo (P , 0.001 for a trend) and exenatide (P , 0.001 for a trend) treatment. Finally, pre-procedural TIMI flow remained significantly associated with MSI when adjusting for exenatide treatment (P , 0.001). ST-segment resolution data were missing from 18 patients. *P-value by Kruskal-Wallis test or one-way analysis of variances. **P , 0.05 for the difference between TIMI flow 0/1 and 2. ***P , 0.05 for the difference between TIMI flow 0/1 and 3. ****P , 0.05 for the difference between TIMI flow 2 and 3.
Collateral flow to the infarct-related artery
Patients with collaterals were more frequently treated with statins at the time of infarction, had pre-infarction angina, had multiple vessels disease, and were treated with exenatide ( Table 3) . Interestingly, there was a non-significant numerically longer time from the first medical contact to balloon in the patients with collateral flow to the infarct-related artery. No differences in MSI ( Figure 2C ), infarct size (Table 3) , or ST-segment resolution (Table 3) were observed. Collateral blood flow was not significantly associated with MSI in the univariable analysis (Table 4) , no interaction between exenatide treatment and collateral flow was observed (P ¼ 0.53), and collateral flow was not associated with MSI, adjusting for exenatide treatment (P ¼ 0.26). Stratifying the patients according to placebo (P ¼ 0.51) or exenatide (P ¼ 0.99) treatment did not change the results.
Discussion
We report an increased MSI in patients with pre-infarction angina compared with patients with no angina. This effect was independent of concomitant medical treatment and collateral flow to the infarct-related artery. Pre-procedural TIMI flow was strongly related to MSI, infarct size, and LVEF. In this regard, TIMI flow 2 appeared to be an intermediary risk factor. Finally, no cardioprotective effect of angiographically visible collateral blood flow to the infarct-related area was observed in terms of MSI or infarct size. This is the first study to evaluate the effect of pre-infarction angina using CMR. The present study suggests that the previously observed improvement in clinical outcome in patients with preinfarction angina 8, 10, 14 is mediated through cardioprotection by increased myocardial salvage. Despite an increase in MSI, the decrease in infarct size did not reach statistical significance. However, a strong trend was observed between the groups in terms of infarct size when adjusting for area at risk in a linear regression analysis. No difference in LVEF was observed, but LVEF is a relatively gross measure of the post-infarction damage, partly due to compensatory hyperkinesia of the non-infarcted myocardium contributing to preserve the global LVEF despite regional dysfunction. The cardioprotective mechanism of pre-infarction angina is not fully elucidated, but ischaemic preconditioning has been suggested as a possible explanation. 31 Cardioprotection by ischaemic preconditioning includes an early protective window (within 1-2 h prior to infarction) and a late window (24 -48 h prior to infarction). 32 Conversely, findings in the present study suggest that pre-infarction angina at any time (,3 months) is associated with cardioprotection, which is in accordance with previous clinical observations. 8, 11 It may be speculated that patients with pre-infarction angina experience ischaemic episodes on a regular basis, both symptomatic and silent, leading to ischaemic preconditioning and cardioprotection. Other explanations for the cardioprotection by pre-infarction angina may be that angina leads to development of collaterals, 33 or/and an increase in the use of pre-infarction medical treatment (e.g. nitrates and aspirin). Although, when adjusting for these variables in a multivariable linear regression analysis, pre-infarction angina remained an independent predictor for MSI, it is noted that patients with pre-infarction angina were more treated with nitrates or ASA and had more collaterals. The effect of preinfarction angina on MSI is suggested to be independent of these confounding factors. Influence of pre-infarction angina, collateral flow, and pre-procedural TIMI flow Previous studies have compared TIMI flow 0/1 with TIMI flow 2/ 3 patients, using CMR to assess infarct size and MSI. 6, 20, 25 Iwakura et al. 26 evaluated pre-procedural TIMI flow, but could not distinguish between pre-procedural TIMI flow 2 and 3 in terms of myocardial damage assessed as CK enzyme release, but only in terms of %systolic wall thickening. We suggest that the difference in clinical outcome related to a 1 grade in pre-procedural TIMI flow, as demonstrated by Ndrepepa et al. 28 in patients with acute coronary syndrome, is due to a difference in MSI and infarct size. However, Ndrepepa et al. did not find pre-procedural TIMI flow to be an independent predictor for clinical outcome when adjusting for post-procedural TIMI flow in their study. Stone et al. 34 found pre-procedural TIMI flow grade 3 to be an independent predictor also when adjusting for post-procedural TIMI flow in patients with STEMI. Nevertheless, pre-procedural TIMI flow seems to be an important indicator for the outcome and myocardial damage in patients with STEMI, and pre-procedural TIMI flow 2 appears to be an intermediate risk factor. These findings confirm the need for fast and proper treatment of STEMI patients in order to improve the pre-procedural TIMI flow and thus increase the myocardial salvage. In the present study, interaction was observed between exenatide treatment and pre-procedural TIMI flow grade, suggesting that the cardioprotective effect of exenatide is most pronounced in patients with low TIMI flow. This confirms previous observations that pre-procedural TIMI flow is a pivotal determinant of reperfusion injury and cardioprotection. One previous study has assessed the association between collaterals and MSI, although the definition of MSI (area at risk by angiogram -infarct size by CMR/LV mass by CMR) was different compared with ours (area at risk by T2-weighted CMR -infarct size by CMR/area at risk by T2-weighted CMR), and area at risk was assessed using an angiogram-based method. 20 The definition used in the present study is widely acceptable and has previously been used. 6, 35 We did not find a relation between collateral blood flow and MSI, and only a weak trend for the relation between collaterals and infarct size. The latter is in accordance with a previous large study evaluating the impact of collaterals on infarct size using CMR. 16 However, this study did not take area at risk into account. It is noteworthy that no difference was observed in infarct size when adjusting for area at risk in our study. The use of oedema to estimate the area at risk has been questioned due to a possible decrease in oedema and area at risk per se in the presence of collaterals. However, no difference in area at risk was observed between patients with and without collaterals in the present study. In contrast, one smaller study has found that patients with well-developed collaterals develop smaller infarct sizes. 20 In addition, collateral blood flow has previously been associated with a decrease in early but not late microvascular obstruction, 16 which is a more appropriate marker for no-reflow than early microvascular obstruction. 36 In the present study, a numerical longer time from the first medical contact to balloon was observed in the patients with collaterals, which may help explain the missing association between collaterals and MSI and infarct size. This also suggests that patients with collaterals have a different clinical presentation, and it may be speculated that some patients with collaterals present clinically as non-STEMI patients despite a total occlusion. The latter issue is highly speculative. Furthermore, since a small numerical difference in MSI and final infarct size was observed, the results may be subject to a type II statistical error. Nonetheless, based on previous findings and results from the present study, the independent cardioprotective benefit of angiographically visible collateral flow in STEMI patients in terms of myocardial damage and salvage seems to be smaller than expected. Therefore, the mere presence of angiographically visible collaterals in STEMI patients should not influence the revascularization strategy in STEMI patients. Influence of pre-infarction angina, collateral flow, and pre-procedural TIMI flow Third, studying the importance of collaterals is problematic due to the confounding role of different baseline characteristics. As demonstrated in the present study, collaterals are less frequent among patients with anterior infarct location, hampering the interpretation of results regarding infarct size and LVEF. In addition, collaterals may not be independent predictors for prognostic. 23 
Limitations
There are some important limitations, which need to be discussed. Patients in this study were randomized to either placebo or exenatide, which could have affected the results. However, stratifying the patients according to or adjusting for treatment allocation in linear regression analyses, the results remained unaltered. A possible confounding role of exenatide appears unlikely, but using all patients in this sub-study increases the statistical power. Despite adjusting for a possible confounding role of any baseline characteristic, there may be unknown confounders. Excluding patients with aborted STEMI may have affected the results. However, no differences in the incidence of pre-infarction angina (P ¼ 0.54) or collaterals (P ¼ 0.33) were observed between the patients with STEMI compared with those with aborted STEMI (data not shown). The assessment of pre-infarction angina depends on the symptoms described by the patients, which does not take into account silent ischaemic and chest pain or discomfort not related to an ischaemic cardiac course. Evaluating pre-infarction angina may further be hampered by possible patients recall bias and may help explain the relative low incidence of pre-infarction angina in the present study. A proper evaluation of pre-infarction ischaemia would require ECG monitoring. Delayed enhancement images were not acquired during the initial scan, and it was therefore not possible to look into the effects on microvascular obstruction. Finally, too few patients were included to stratify the patients according to a 1 grade change in Rentrop class.
Conclusion
Pre-infarction angina increases MSI in patients with STEMI, supporting the theory that pre-infarction angina leads to ischaemic preconditioning. As opposed to the presence of angiographically visible collateral flow to the infarct area, pre-procedural TIMI flow is strongly associated with MSI.
